Table 2. Prevalence of antimicrobial resistance in selected bacteria (all clinical isolates) isolated from 12 major hospitals, including National Taiwan University Hospital (NTUH), in Taiwan in 2000 and in all clinical isolates and isolates causing nosocomial infections from NTUH in 2000a .
| Resistant pathogen | % of isolates |
|
|---|---|---|
| 2,000 (12 hospitals) (clinical) | 2,000 (NTUH) (clinical/nosocomial) | |
| Methicillin-resistant Staphylococcus aureus | 53-83 | 65/74 |
| Erythromycin-resistant beta-hemolytic streptococci | 30-51 | 34/- |
| Penicillin-nonsusceptible Streptococcus pneumoniae | 60-84 | 77/- |
| Erythromycin-resistant S. pneumoniae | 67-100 | 89/- |
| Gentamicin-resistant (high-level) enterococci | 36-54 | 48/54 |
| Vancomycin-resistant enterococci | 1-3 | 3/2 |
| Ampicillin-resistant H. influenzae | 45-73 | 61/- |
| Cefotaxime-resistant Escherichia coli | 5-19 | 12/19 |
| Ciprofloxacin-resistant E. coli | 11-33 | 20/29 |
| Cefotaxime-resistant Klebsiella pneumoniae | 4-34 | 9/18 |
| Ciprofloxacin-resistant K. pneumoniae | 5-33 | 9/16 |
| Cefotaxime-resistant E. cloacae | 36-68 | 45/49 |
| Ampicillin-resistant non-typhoid Salmonella | 44-69 | 56/- |
| Cefotaxime-resistant non- typhoid Salmonella | 1-4 | 2/- |
| Quinolone resistant non-typhi Salmonella | 0-16 | 0/- |
| Ceftazidime-resistant Pseudomonas aeruginosa | 4-21 | 13/10 |
| Imipenem-resistant P. aeruginosa | 3-16 | 14/10 |
| Ciprofloxacin-resistant P. aeruginosa | 10-36 | 15/10 |
| Imipenem-resistant Acinetobacter baumannii | 0-19 | 19/16 |
| Ciprofloxacin-resistant A. baumannii | 54-74 | 54/42 |
aSusceptibility of these bacteria was determined by the standard disk-diffusion method.